Boehringer Ingelheim Pharmaceuticals has announced the permanent discontinuation of Persantine (dipyridamole) tablets and its authorized generics. The decision to discontinue the product is business-related and not due to product safety or efficacy.
The 25mg, 50mg, and 75mg tablets strengths of the brand and authorized generic will be discontinued. The company expects adequate market supply of Persantine tablets through May 2016 and authorized generic, dipyridamole tablets through August 2017.
Persantine is indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.
For more information call (800) 542-6257 or visit FDA.gov.